Q-omics provides the consensus-scored GRIN2D profile across patient tissues and cancer cell-line models. GRIN2D expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GRIN2D is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, GRIN2D RNA expression shows 16,500 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where GRIN2D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIN2D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIN2D survival associations across molecular data types. GRIN2D RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIN2D RNA expression–survival associations across cancer types. High GRIN2D expression shows unfavorable associations in ACC, KIRC, UVM and LIHC, but favorable associations in UCEC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GRIN2D RNA expression.
This table summarizes GRIN2D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GRIN2D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIN2D shows higher tumor expression in COAD, HNSC, BLCA, LUAD, KIRC and STAD. The COAD box plot shows higher GRIN2D RNA expression in tumor versus normal tissue (log2 FC = +4.450, t-test p < 0.001).
This table shows molecular features associated with GRIN2D in patient tissues and cancer cell lines. In patient samples, GRIN2D shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIN2D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
